Best CMMS for Contract Manufacturers: Multi-Customer Asset Management

Contract manufacturers (CMs) and contract manufacturing organizations (CMOs) face CMMS requirements fundamentally different from dedicated manufacturers: they manage equipment used for multiple customer products, some equipment is customer-owned rather than CM-owned, and maintenance records may be subject to customer audit rights. Key CMMS requirements unique to contract manufacturing: multi-customer asset classification (CM-owned production equipment versus customer-owned dedicated equipment), maintenance cost allocation by customer (enabling billing of customer-attributable maintenance costs), customer audit access — some contracts give customers the right to audit maintenance records for their dedicated equipment, customer equipment handoff documentation — when customer-dedicated equipment moves between CM and customer, a documented equipment condition record protects both parties, and separation of maintenance records for different customer programs to support compartmentalization. In pharmaceutical contract manufacturing, FDA 21 CFR Part 211 equipment maintenance requirements apply independently for each customer drug product manufactured, creating overlapping compliance obligations that CMMS must manage simultaneously.

Pharmaceutical contract manufacturing organizations (CMOs) producing drug products under contract face CMMS requirements driven by FDA cGMP regulations that apply to every customer program. 21 CFR Part 211 Subpart D requires written procedures for equipment cleaning and maintenance, equipment maintenance log records, and documentation that equipment used in production is clean and in proper operating condition. For multi-customer CMOs producing multiple drug products on shared equipment, CMMS must document equipment changeover, cleaning validation completion, and maintenance status separately for each production campaign. FDA inspectors specifically examine whether CMOs have controlled cross-contamination risk from shared equipment, and CMMS maintenance records are part of this inspection evidence. Clinical-stage CMOs serving early development customers have additional flexibility but commercial manufacturing CMOs must demonstrate FDA compliance through auditable CMMS records. The CMO business model — where losing a single large customer can dramatically affect business viability — makes FDA audit readiness a competitive differentiator that CMMS directly enables.

Contract manufacturers should prioritize CMMS with flexible asset ownership classification, customer-level access control, maintenance cost allocation reporting by customer, and audit trail capability suitable for customer and regulatory audits. The multi-customer complexity of contract manufacturing means that CMMS configuration is more involved than single-product dedicated manufacturing — plan for 20 to 30% more configuration time than standard deployment estimates. For pharmaceutical CMOs, CMMS validation per 21 CFR Part 11 is required, and the validation scope is more complex than single-product manufacturers because the validated state must cover all customer product scenarios. Customer-owned equipment management — tracking customers who own specific equipment assets, documenting handoffs with condition records, and alerting customers to scheduled maintenance — is a capability specifically to verify in CMMS evaluation demos. Most standard CMMS platforms support asset ownership as a field value but not as a functional access control and reporting dimension, making custom configuration necessary. Fabrico and Fiix both provide the flexible access control and reporting architecture that contract manufacturing multi-customer management requires.